MedTrace Logo

A Study to Evaluate Safety and Tolerability of MIV-711 in Osteoarthritis Patients

NCT03037489 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2019-03-18

Study results available
· View outcomes & findings →

Summary

This is a multicentre, open-label, one-arm Phase II extension study to evaluate the safety and tolerability of MIV-711 in patients with knee joint osteoarthritis (OA).

Conditions

  • Osteoarthritis, Knee

Interventions

DRUG

MIV-711

MIV-711 administered orally once daily

Sponsors & Collaborators

  • Medivir

    lead INDUSTRY

Principal Investigators

  • Philip Conaghan, Professor · Leeds Institute of Rheumatic and Musculoskeletal Medicine

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
40 Years
Max Age
81 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-09-30
Primary Completion
2017-11-28
Completion
2017-11-28

Countries

  • Bulgaria
  • Georgia
  • Germany
  • Moldova

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03037489 on ClinicalTrials.gov